Groundbreaking research has identified Epstein-Barr virus (EBV) as a possible trigger for the autoimmune disease lupus. According to scientists, EBV can cause immune cells to "go rogue" and mistakenly attack the body's own tissues, leading to the chronic condition.
The study suggests that EBV is responsible for 100% of lupus cases, according to Prof William Robinson, a professor of immunology and rheumatology at Stanford University. The researchers believe that this discovery could lead to the development of new therapies that can fundamentally treat and benefit patients with lupus.
Lupus is a chronic autoimmune condition that affects about 69,000 people in the UK. It causes joint and muscle pain, extreme tiredness, and skin rashes, and there is no known cure for the condition. Previous epidemiological surveys have hinted at a link between EBV and lupus, which has been proven true in this latest study.
The researchers used high-precision genetic sequencing to compare the number and type of B cells that are infected with EBV in patients with lupus versus healthy controls. The results showed that about 25 times more B cells were infected with EBV in patients with lupus, compared to those without the condition.
When these cells were infected with EBV, they became hyperactive and not only targeted antigens inside the body but also recruited other immune cells to join the attack. This finding suggests that EBV is responsible for flipping the balance of these cells into an autoimmune response that mediates lupus.
While this discovery has significant implications, researchers stress that there are other well-known risk factors that contribute to a person's susceptibility to lupus, such as hormones and genetic background. However, the study provides new hope for developing treatments for severe cases of lupus.
The findings have been welcomed by experts in the field, including Prof Guy Gorochov, who described the work as "impressive". The researchers believe that this discovery could lead to clinical trials for an EBV vaccine and repurposing cancer treatments designed to wipe out B cells.
The study suggests that EBV is responsible for 100% of lupus cases, according to Prof William Robinson, a professor of immunology and rheumatology at Stanford University. The researchers believe that this discovery could lead to the development of new therapies that can fundamentally treat and benefit patients with lupus.
Lupus is a chronic autoimmune condition that affects about 69,000 people in the UK. It causes joint and muscle pain, extreme tiredness, and skin rashes, and there is no known cure for the condition. Previous epidemiological surveys have hinted at a link between EBV and lupus, which has been proven true in this latest study.
The researchers used high-precision genetic sequencing to compare the number and type of B cells that are infected with EBV in patients with lupus versus healthy controls. The results showed that about 25 times more B cells were infected with EBV in patients with lupus, compared to those without the condition.
When these cells were infected with EBV, they became hyperactive and not only targeted antigens inside the body but also recruited other immune cells to join the attack. This finding suggests that EBV is responsible for flipping the balance of these cells into an autoimmune response that mediates lupus.
While this discovery has significant implications, researchers stress that there are other well-known risk factors that contribute to a person's susceptibility to lupus, such as hormones and genetic background. However, the study provides new hope for developing treatments for severe cases of lupus.
The findings have been welcomed by experts in the field, including Prof Guy Gorochov, who described the work as "impressive". The researchers believe that this discovery could lead to clinical trials for an EBV vaccine and repurposing cancer treatments designed to wipe out B cells.